In a report released today, David Westenberg from Piper Sandler reiterated a Buy rating on Akoya Biosciences (AKYA – Research Report), with a price target of $11.00. The company’s shares opened today at $4.14.
Westenberg covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, Illumina, and Zoetis. According to TipRanks, Westenberg has an average return of -7.0% and a 34.85% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akoya Biosciences with a $10.00 average price target, which is a 141.55% upside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $14.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $13.73 and a one-year low of $3.04. Currently, Akoya Biosciences has an average volume of 159.8K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AKYA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akoya Biosciences (AKYA) Company Description:
Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.
Read More on AKYA:
- Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
- Akoya Biosciences to showcase spatial biology 2.0 solutions
- Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
- Akoya Biosciences price target lowered to $8 from $15 at Morgan Stanley
- Akoya Biosciences announces publication on ultrahigh-plex spatial phenotyping
